https://www.selleckchem.com/CDK.html
40 months (1.10-13.33). No EVL-related adverse events were observed. Statistically significant differences were observed in the bleeding rate at 3 years between propranolol and EVL groups (6/32, 21.9% vs 1/32, 3.2%; P less then 0.02). The hazard ratio for bleeding for patients treated with propranolol compared with those treated with EVL was 2.6 (1.53-3.67; IC 95%). CONCLUSIONS EVL is a safe and effective treatment to prevent upper GI bleeding in pediatric patients with PH. BACKGROUND AND AIMS We perform a meta-analysis of all published studies to d
Curtir
Comentario
Compartilhar
